Efficacy of Low-Dose FK506 in the Treatment of Myasthenia gravis – A Randomized Pilot Study
To determine the efficacy of low-dose FK506 in the treatment of myasthenia gravis (MG), untreated de novo patients were randomly selected to receive treatment with (n = 18) or without (n = 16) FK506, and were evaluated for 1 year after treatment with limitation of daily dose of prednisolone. Low-dos...
Gespeichert in:
| Veröffentlicht in: | European neurology 2005-01, Vol.53 (3), p.146-150 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 150 |
|---|---|
| container_issue | 3 |
| container_start_page | 146 |
| container_title | European neurology |
| container_volume | 53 |
| creator | Nagane, Yuriko Utsugisawa, Kimiaki Obara, Daiji Kondoh, Ryushi Terayama, Yasuo |
| description | To determine the efficacy of low-dose FK506 in the treatment of myasthenia gravis (MG), untreated de novo patients were randomly selected to receive treatment with (n = 18) or without (n = 16) FK506, and were evaluated for 1 year after treatment with limitation of daily dose of prednisolone. Low-dose FK506 reduced the duration of early-phase therapy in hospital (p < 0.05) and the need for combined therapy with plasmapheresis and high-dose intravenous methylprednisolone or high-dose intravenous methylprednisolone alone (p < 0.05). It also reduced the daily dose of prednisolone (p < 0.05) required to maintain minimal manifestations of MGFA postintervention status. None of the patients exhibited significant side effects up to 1 year after treatment. These findings suggest that low-dose FK506 is safe and efficacious for the treatment of de novo MG patients. |
| doi_str_mv | 10.1159/000085833 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_proquest_miscellaneous_20921234</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>855130421</sourcerecordid><originalsourceid>FETCH-LOGICAL-c457t-1a6876f853ad5c792dc6c7249a2ee3a3fbe703aff78ecfbde71547d6b981a5c43</originalsourceid><addsrcrecordid>eNqF0c9rFDEUB_AgFrtdPXgWJBQq9DCa35kcS3-ouKJoPcrwNpPU1JlJm8wo66n_g_-hf4nZ7tKCF3N5JHzyHo8vQk8peUmpNK9IObWsOX-AZlQwWhlD-UM0I4SKihPGdtFezpflKo2uH6HdUssXo2fo66n3wYJd4ejxIv6sTmJ2-OydJAqHAY_fHD5PDsbeDeOavF9BLo9DAHyR4EfI-M_Nb3yEP8HQxj78ci3-GLo44s_j1K4eox0PXXZPtnWOvpydnh-_qRYfXr89PlpUVkg9VhRUrZWvJYdWWm1Ya5XVTBhgznHgfuk04eC9rp31y9ZpKoVu1dLUFKQVfI5ebPpepXg9uTw2fcjWdR0MLk65UdoIIbn-L2TEMMr4uuP-P_AyTmkoSzTUCMMUJ7ygww2yKeacnG-uUughrRpKmnUyzV0yxT7fNpyWvWvv5TaKAg62ALKFzicYbMj3TtXqdok5erZx3yFduHQHNmP-Al1MnKk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>194926303</pqid></control><display><type>article</type><title>Efficacy of Low-Dose FK506 in the Treatment of Myasthenia gravis – A Randomized Pilot Study</title><source>Karger Journals</source><source>MEDLINE</source><creator>Nagane, Yuriko ; Utsugisawa, Kimiaki ; Obara, Daiji ; Kondoh, Ryushi ; Terayama, Yasuo</creator><creatorcontrib>Nagane, Yuriko ; Utsugisawa, Kimiaki ; Obara, Daiji ; Kondoh, Ryushi ; Terayama, Yasuo</creatorcontrib><description>To determine the efficacy of low-dose FK506 in the treatment of myasthenia gravis (MG), untreated de novo patients were randomly selected to receive treatment with (n = 18) or without (n = 16) FK506, and were evaluated for 1 year after treatment with limitation of daily dose of prednisolone. Low-dose FK506 reduced the duration of early-phase therapy in hospital (p < 0.05) and the need for combined therapy with plasmapheresis and high-dose intravenous methylprednisolone or high-dose intravenous methylprednisolone alone (p < 0.05). It also reduced the daily dose of prednisolone (p < 0.05) required to maintain minimal manifestations of MGFA postintervention status. None of the patients exhibited significant side effects up to 1 year after treatment. These findings suggest that low-dose FK506 is safe and efficacious for the treatment of de novo MG patients.</description><identifier>ISSN: 0014-3022</identifier><identifier>EISSN: 1421-9913</identifier><identifier>DOI: 10.1159/000085833</identifier><identifier>PMID: 15900097</identifier><identifier>CODEN: EUNEAP</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Adult ; Aged ; Anti-Inflammatory Agents - therapeutic use ; Biological and medical sciences ; Diseases of striated muscles. Neuromuscular diseases ; Dose-Response Relationship, Drug ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Humans ; Immunomodulators ; Immunosuppressive Agents - therapeutic use ; Interleukin-2 - blood ; Male ; Medical sciences ; Methylprednisolone - therapeutic use ; Middle Aged ; Myasthenia Gravis - blood ; Myasthenia Gravis - drug therapy ; Neurology ; Original Paper ; Pharmacology. Drug treatments ; Pilot Projects ; Plasmapheresis - methods ; Statistics, Nonparametric ; Tacrolimus - therapeutic use ; Time Factors ; Treatment Outcome</subject><ispartof>European neurology, 2005-01, Vol.53 (3), p.146-150</ispartof><rights>2005 S. Karger AG, Basel</rights><rights>2005 INIST-CNRS</rights><rights>Copyright (c) 2005 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c457t-1a6876f853ad5c792dc6c7249a2ee3a3fbe703aff78ecfbde71547d6b981a5c43</citedby><cites>FETCH-LOGICAL-c457t-1a6876f853ad5c792dc6c7249a2ee3a3fbe703aff78ecfbde71547d6b981a5c43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2423,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16869445$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15900097$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nagane, Yuriko</creatorcontrib><creatorcontrib>Utsugisawa, Kimiaki</creatorcontrib><creatorcontrib>Obara, Daiji</creatorcontrib><creatorcontrib>Kondoh, Ryushi</creatorcontrib><creatorcontrib>Terayama, Yasuo</creatorcontrib><title>Efficacy of Low-Dose FK506 in the Treatment of Myasthenia gravis – A Randomized Pilot Study</title><title>European neurology</title><addtitle>Eur Neurol</addtitle><description>To determine the efficacy of low-dose FK506 in the treatment of myasthenia gravis (MG), untreated de novo patients were randomly selected to receive treatment with (n = 18) or without (n = 16) FK506, and were evaluated for 1 year after treatment with limitation of daily dose of prednisolone. Low-dose FK506 reduced the duration of early-phase therapy in hospital (p < 0.05) and the need for combined therapy with plasmapheresis and high-dose intravenous methylprednisolone or high-dose intravenous methylprednisolone alone (p < 0.05). It also reduced the daily dose of prednisolone (p < 0.05) required to maintain minimal manifestations of MGFA postintervention status. None of the patients exhibited significant side effects up to 1 year after treatment. These findings suggest that low-dose FK506 is safe and efficacious for the treatment of de novo MG patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Diseases of striated muscles. Neuromuscular diseases</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Interleukin-2 - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methylprednisolone - therapeutic use</subject><subject>Middle Aged</subject><subject>Myasthenia Gravis - blood</subject><subject>Myasthenia Gravis - drug therapy</subject><subject>Neurology</subject><subject>Original Paper</subject><subject>Pharmacology. Drug treatments</subject><subject>Pilot Projects</subject><subject>Plasmapheresis - methods</subject><subject>Statistics, Nonparametric</subject><subject>Tacrolimus - therapeutic use</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0014-3022</issn><issn>1421-9913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqF0c9rFDEUB_AgFrtdPXgWJBQq9DCa35kcS3-ouKJoPcrwNpPU1JlJm8wo66n_g_-hf4nZ7tKCF3N5JHzyHo8vQk8peUmpNK9IObWsOX-AZlQwWhlD-UM0I4SKihPGdtFezpflKo2uH6HdUssXo2fo66n3wYJd4ejxIv6sTmJ2-OydJAqHAY_fHD5PDsbeDeOavF9BLo9DAHyR4EfI-M_Nb3yEP8HQxj78ci3-GLo44s_j1K4eox0PXXZPtnWOvpydnh-_qRYfXr89PlpUVkg9VhRUrZWvJYdWWm1Ya5XVTBhgznHgfuk04eC9rp31y9ZpKoVu1dLUFKQVfI5ebPpepXg9uTw2fcjWdR0MLk65UdoIIbn-L2TEMMr4uuP-P_AyTmkoSzTUCMMUJ7ygww2yKeacnG-uUughrRpKmnUyzV0yxT7fNpyWvWvv5TaKAg62ALKFzicYbMj3TtXqdok5erZx3yFduHQHNmP-Al1MnKk</recordid><startdate>20050101</startdate><enddate>20050101</enddate><creator>Nagane, Yuriko</creator><creator>Utsugisawa, Kimiaki</creator><creator>Obara, Daiji</creator><creator>Kondoh, Ryushi</creator><creator>Terayama, Yasuo</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20050101</creationdate><title>Efficacy of Low-Dose FK506 in the Treatment of Myasthenia gravis – A Randomized Pilot Study</title><author>Nagane, Yuriko ; Utsugisawa, Kimiaki ; Obara, Daiji ; Kondoh, Ryushi ; Terayama, Yasuo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c457t-1a6876f853ad5c792dc6c7249a2ee3a3fbe703aff78ecfbde71547d6b981a5c43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Diseases of striated muscles. Neuromuscular diseases</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Interleukin-2 - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methylprednisolone - therapeutic use</topic><topic>Middle Aged</topic><topic>Myasthenia Gravis - blood</topic><topic>Myasthenia Gravis - drug therapy</topic><topic>Neurology</topic><topic>Original Paper</topic><topic>Pharmacology. Drug treatments</topic><topic>Pilot Projects</topic><topic>Plasmapheresis - methods</topic><topic>Statistics, Nonparametric</topic><topic>Tacrolimus - therapeutic use</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nagane, Yuriko</creatorcontrib><creatorcontrib>Utsugisawa, Kimiaki</creatorcontrib><creatorcontrib>Obara, Daiji</creatorcontrib><creatorcontrib>Kondoh, Ryushi</creatorcontrib><creatorcontrib>Terayama, Yasuo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>European neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nagane, Yuriko</au><au>Utsugisawa, Kimiaki</au><au>Obara, Daiji</au><au>Kondoh, Ryushi</au><au>Terayama, Yasuo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of Low-Dose FK506 in the Treatment of Myasthenia gravis – A Randomized Pilot Study</atitle><jtitle>European neurology</jtitle><addtitle>Eur Neurol</addtitle><date>2005-01-01</date><risdate>2005</risdate><volume>53</volume><issue>3</issue><spage>146</spage><epage>150</epage><pages>146-150</pages><issn>0014-3022</issn><eissn>1421-9913</eissn><coden>EUNEAP</coden><abstract>To determine the efficacy of low-dose FK506 in the treatment of myasthenia gravis (MG), untreated de novo patients were randomly selected to receive treatment with (n = 18) or without (n = 16) FK506, and were evaluated for 1 year after treatment with limitation of daily dose of prednisolone. Low-dose FK506 reduced the duration of early-phase therapy in hospital (p < 0.05) and the need for combined therapy with plasmapheresis and high-dose intravenous methylprednisolone or high-dose intravenous methylprednisolone alone (p < 0.05). It also reduced the daily dose of prednisolone (p < 0.05) required to maintain minimal manifestations of MGFA postintervention status. None of the patients exhibited significant side effects up to 1 year after treatment. These findings suggest that low-dose FK506 is safe and efficacious for the treatment of de novo MG patients.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>15900097</pmid><doi>10.1159/000085833</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-3022 |
| ispartof | European neurology, 2005-01, Vol.53 (3), p.146-150 |
| issn | 0014-3022 1421-9913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20921234 |
| source | Karger Journals; MEDLINE |
| subjects | Adult Aged Anti-Inflammatory Agents - therapeutic use Biological and medical sciences Diseases of striated muscles. Neuromuscular diseases Dose-Response Relationship, Drug Drug Therapy, Combination Female Follow-Up Studies Humans Immunomodulators Immunosuppressive Agents - therapeutic use Interleukin-2 - blood Male Medical sciences Methylprednisolone - therapeutic use Middle Aged Myasthenia Gravis - blood Myasthenia Gravis - drug therapy Neurology Original Paper Pharmacology. Drug treatments Pilot Projects Plasmapheresis - methods Statistics, Nonparametric Tacrolimus - therapeutic use Time Factors Treatment Outcome |
| title | Efficacy of Low-Dose FK506 in the Treatment of Myasthenia gravis – A Randomized Pilot Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T21%3A36%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20Low-Dose%20FK506%20in%20the%20Treatment%20of%20Myasthenia%20gravis%20%E2%80%93%20A%20Randomized%20Pilot%20Study&rft.jtitle=European%20neurology&rft.au=Nagane,%20Yuriko&rft.date=2005-01-01&rft.volume=53&rft.issue=3&rft.spage=146&rft.epage=150&rft.pages=146-150&rft.issn=0014-3022&rft.eissn=1421-9913&rft.coden=EUNEAP&rft_id=info:doi/10.1159/000085833&rft_dat=%3Cproquest_karge%3E855130421%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=194926303&rft_id=info:pmid/15900097&rfr_iscdi=true |